Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…
If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…
Modular Medical (NASDAQ: MODD), a potential disruptor in diabetes care technology, is rapidly moving from visionary concept to tangible innovation as it propels its FDA cleared MODD1 insulin patch pump toward commercial launch. The company has recently validated its MODD1 cartridge manufacturing…
In a move that has sent shockwaves of excitement through the biotech community, Soleno Therapeutics (NASDAQ: SLNO, Up approx. +40% on Thursday) has successfully secured FDA approval for VYKAT XR, the first-ever treatment for hyperphagia in Prader-Willi syndrome (PWS). This rare genetic…